Major deal today in the generic-drug arena: #msg-30792830.
Inasmuch as BRL was emerging as a serious contender in the FoB arena (based on its 2007 acquisition of Pliva), the TEVA-BRL deal reduces the number of FoB players by one.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.